Cann Group Limited: Resignation and appointment of Company Secretary and Acting Chief Financial Officer

9 December 2019

Melbourne: – Cann Group Limited (Company) today advises that Ms Geraldine Farrell has been appointed as Company Secretary and Ms Reena Dahiya has been appointed as Acting Chief Financial Officer, effective 6 December 2019.

Ms Farrell has over 25 years’ experience in the legal profession in commercial, corporate and intellectual property law, and recent experience as an executive and as a Company Secretary for a NASDAQ-listed entity. She is a chartered secretary and qualified solicitor, has a Graduate Diploma in Applied Corporate Governance, is a Fellow of the Governance Institute of Australia and a Fellow of the Chartered Governance Institute. With a strong background in corporate governance, she has experience in securities law compliance and statutory financial reporting and is an experienced director and graduate of the Australian Institute of Company Directors.

Ms Dahiya is a Fellow of CPA Australia with over 25 years’ experience within finance and accounting across a diverse range of industries. She has held finance leadership roles across large global and Australian-based companies, including secondments overseas. Ms Dahiya is highly experienced in organisational strategy, controllership, governance, audit, business transformation and reporting, and has led finance, IT and HR functions.

Ms Farrell and Ms Dahiya replace Mr Richard Baker who has resigned as Company Secretary and Chief Financial Officer, effective 6 December 2019. The Board acknowledges and thanks Mr Baker for the contribution he has made since March 2015.

Read the full media release here: Cann Group December 2019

For further information please contact:

Peter Crock
Cann Group Limited
+61 3 9095 7088

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 498 000 762

Matthew Wright
NWR Communications +
61 451 896 420

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients.

Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada’s largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.5% shareholding


News & opinion

Member Directory